Thrombopoietin Receptor

Totrombopag (SB559448) 是对RSV 聚合酶有作用的候选化合物。

Eltrombopag (SB-497115-GR) 是一种具有巨核细胞生成刺激活性的口服活性血小板生成素受体激动剂，可结合并刺激血小板血小板生成素受体，用于血小板减少的某些病症研究。

Butyzamide 是一种有效的 可口服的Mpl 激活剂，是一种对血小板生成素(TPO)受体具有拮抗作用的新型非肽基分子，促进表达人Mpl (hMpl)的和小鼠pro B 细胞株Ba/F3的增殖，诱导JAK2、STAT3、STAT5和MAPK 的磷酸化。Butyzamide 在小鼠异种移植试验中有助于提升血小板水平。

Avatrombopag (YM477) 是一种新型口服血小板生成素 (TPO) 受体激动剂，可激活 TPO 受体并增加巨核细胞增殖/分化和血小板生成。

Imidazole 是一种高极性化合物，是一种平面五元环，已被广泛用作腐蚀抑制剂。

Eltrombopag Olamine (Eltrombopag diethanolamine salt) 是 Eltrombopag 的口服活性乙醇胺盐，是一种血小板生成素(TPO)受体激动剂，用于血小板减少的某些病症研究。

Lusutrombopag (Mulpleta) 是一种口服生物可利用的小分子血小板生成素 (TPO) 受体激动剂，用于选择性侵入性手术前患有血小板减少症的慢性肝病的患者。

4”-O-Glucosylvitexin (glucosylvitexin) 是一种黄酮类化合物，提取自山楂叶中，具有生物活性。

Hetrombopag olamine is a non-peptide thrombopoietin (TPO) receptor agonist with oral activity.

Hetrombopag 是一种 thrombopoietin receptor 的有效激动剂。Hetrombopag 具有良好的耐受性且安全性可控。Hetrombopag 具有潜力进行免疫性血小板减少症的研究。

Avatrombopag, also known as AKR-501, YM477, AS 1670542 or E5501, is a novel orally-active thrombopoietin (TPO) receptor agonist. AKR-501 specifically targeted the TPO receptor and stimulated megakaryocytopoiesis throughout the development and maturation of megakaryocytes just as rhTPO did. AKR-501 may be useful in the treatment of patients with thrombocytopenia. Avatrombopag was first approved in 2018.

(E/Z)-Eltrombopag 13C4 ((E/Z)-SB-497115 13C4) is a mixture complex of E-Eltrombopag and Z-Eltrombopag, with 13C labeled. Z-Eltrombopag is a thrombopoietin (TPO) receptor agonist developed for certain conditions that lead to thrombocytopenia.

Eltrombopag methyl ester，一种Eltrombopag衍生物，为促血小板生成素(Tpo)受体激动剂，旨在促进血小板生成，用于研究特定类型的血小板减少症。

MF266-1, a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of osteoarthritis and rheumatoid.

TPO agonist 1 is a thrombopoietin agonist. It would be useful as promoters of thrombopoiesis and megakaryocytopoiesis to treat thrombocytopenia.

Totrombopag, also known LGD-4665, GSK2285921 and SB559448, is an oral thromobopoietin receptor agonist, is being developed as a new generation small molecule thrombopoietin (TPO) mimetic. It is a highly selective and potent agonist of the TPO receptor and therefore induces differentiation and proliferation of megakaryocytes. The pharmacologic characteristics indicate potential therapeutic use in thrombocytopenic patients with a variety of clinical etiologies.

Rafutrombopag 是一种血小板生成素 (TPO) 激动剂。

Avatrombopag hydrochloride (AKR-501) is an orally active, nonpeptide agonist of the thrombopoietin (TPO) receptor with an EC 50 of 3.3 nM. It effectively mimics the biological activities of TPO, stimulating platelet production by activating the intracellular signaling system and facilitating the generation of platelets and megakaryocytes from hemopoietic precursor cells. Additionally, Avatrombopag hydrochloride serves as a substrate for cytochrome P450 (CYP) 2C9 and CYP3A.

PKHB1 是具有抗肿瘤活性的Thrombospondin-1肽模拟物。它能在乳腺癌细胞中引起线粒体变化、ROS产生、细胞内Ca+积聚以及钙依赖性细胞死亡。PKHB1 通过诱导乳腺癌细胞的免疫原性细胞死亡来激活免疫系统。